Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Anastasios Ntanasis-Stathopoulos, Panagiotis Malandrakis, Efstathios Kastritis, Ourania E. Tsitsilonis, Meletios A. Dimopoulos, Evangelos Terpos, Maria Gavriatopoulou
{"title":"评估最小残留疾病阴性作为多发性骨髓瘤治疗疗效的替代终点：随机对照试验的荟萃分析","authors":"Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Anastasios Ntanasis-Stathopoulos, Panagiotis Malandrakis, Efstathios Kastritis, Ourania E. Tsitsilonis, Meletios A. Dimopoulos, Evangelos Terpos, Maria Gavriatopoulou","doi":"10.1002/ajh.27582","DOIUrl":null,"url":null,"abstract":"<p>This meta-analysis examined the association between minimal residual disease (MRD) negativity and survival outcomes in 15 304 patients with multiple myeloma (MM) enrolled in randomized controlled trials published until June 2, 2024. Overall, there was a significant, negative and strong association between MRD negativity odds ratios and survival hazard ratios (β_PFS = -0.20, <i>p</i> < 0.001, β_OS = -0.12, <i>p</i> = 0.023). These associations remained significant for newly diagnosed patients (β_PFS = -0.35, <i>p</i> < 0.001), and they were consistent but not significant for relapsed/refractory patients (β_PFS = -0.06, <i>p</i> = 0.635). Sustained MRD negativity at 1 year was strongly correlated with prolonged PFS (β_PFS = -0.30, <i>p</i> < 0.001). In conclusion, this comprehensive meta-analysis supports MRD as a surrogate for survival in MM.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"100 3","pages":"427-438"},"PeriodicalIF":10.1000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.27582","citationCount":"0","resultStr":"{\"title\":\"Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials\",\"authors\":\"Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Anastasios Ntanasis-Stathopoulos, Panagiotis Malandrakis, Efstathios Kastritis, Ourania E. Tsitsilonis, Meletios A. Dimopoulos, Evangelos Terpos, Maria Gavriatopoulou\",\"doi\":\"10.1002/ajh.27582\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>This meta-analysis examined the association between minimal residual disease (MRD) negativity and survival outcomes in 15 304 patients with multiple myeloma (MM) enrolled in randomized controlled trials published until June 2, 2024. Overall, there was a significant, negative and strong association between MRD negativity odds ratios and survival hazard ratios (β_PFS = -0.20, <i>p</i> < 0.001, β_OS = -0.12, <i>p</i> = 0.023). These associations remained significant for newly diagnosed patients (β_PFS = -0.35, <i>p</i> < 0.001), and they were consistent but not significant for relapsed/refractory patients (β_PFS = -0.06, <i>p</i> = 0.635). Sustained MRD negativity at 1 year was strongly correlated with prolonged PFS (β_PFS = -0.30, <i>p</i> < 0.001). In conclusion, this comprehensive meta-analysis supports MRD as a surrogate for survival in MM.</p>\",\"PeriodicalId\":7724,\"journal\":{\"name\":\"American Journal of Hematology\",\"volume\":\"100 3\",\"pages\":\"427-438\"},\"PeriodicalIF\":10.1000,\"publicationDate\":\"2025-01-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.27582\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ajh.27582\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Hematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ajh.27582","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
这项荟萃分析研究了15304名多发性骨髓瘤（MM）患者的最小残留病（MRD）阴性与生存结果之间的关系，这些患者参加了随机对照试验，发表于2024年6月2日。总体而言，MRD阴性优势比与生存风险比之间存在显著的负相关和强相关（β_PFS = -0.20, p < 0.001, β_OS = -0.12, p = 0.023）。这些相关性在新诊断患者中仍然显著（β_PFS = -0.35, p < 0.001），在复发/难治性患者中也一致但不显著（β_PFS = -0.06, p = 0.635）。1年MRD持续阴性与PFS延长密切相关（β_PFS = -0.30, p < 0.001）。总之，这项综合荟萃分析支持MRD作为MM患者生存率的替代指标。
Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
This meta-analysis examined the association between minimal residual disease (MRD) negativity and survival outcomes in 15 304 patients with multiple myeloma (MM) enrolled in randomized controlled trials published until June 2, 2024. Overall, there was a significant, negative and strong association between MRD negativity odds ratios and survival hazard ratios (β_PFS = -0.20, p < 0.001, β_OS = -0.12, p = 0.023). These associations remained significant for newly diagnosed patients (β_PFS = -0.35, p < 0.001), and they were consistent but not significant for relapsed/refractory patients (β_PFS = -0.06, p = 0.635). Sustained MRD negativity at 1 year was strongly correlated with prolonged PFS (β_PFS = -0.30, p < 0.001). In conclusion, this comprehensive meta-analysis supports MRD as a surrogate for survival in MM.
期刊介绍：
The American Journal of Hematology offers extensive coverage of experimental and clinical aspects of blood diseases in humans and animal models. The journal publishes original contributions in both non-malignant and malignant hematological diseases, encompassing clinical and basic studies in areas such as hemostasis, thrombosis, immunology, blood banking, and stem cell biology. Clinical translational reports highlighting innovative therapeutic approaches for the diagnosis and treatment of hematological diseases are actively encouraged.The American Journal of Hematology features regular original laboratory and clinical research articles, brief research reports, critical reviews, images in hematology, as well as letters and correspondence.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
